Upgrades Cellectis (NASDAQ:CLLS) to “Hold”

Cellectis (NASDAQ:CLLSGet Rating) was upgraded by from a “sell” rating to a “hold” rating in a report released on Thursday.

A number of other equities analysts also recently weighed in on the stock. Wells Fargo & Company downgraded shares of Cellectis from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $39.00 to $16.00 in a research note on Thursday, January 6th. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, January 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. According to, the company currently has a consensus rating of “Hold” and an average target price of $21.00.

NASDAQ:CLLS opened at $3.64 on Thursday. The stock has a market capitalization of $165.59 million, a P/E ratio of -1.44 and a beta of 2.25. The company has a current ratio of 4.57, a quick ratio of 4.57 and a debt-to-equity ratio of 0.08. Cellectis has a 1 year low of $3.43 and a 1 year high of $19.68. The firm has a 50 day moving average of $4.23 and a 200-day moving average of $6.96.

Cellectis (NASDAQ:CLLSGet Rating) last issued its quarterly earnings data on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.05) by $0.50. Cellectis had a negative return on equity of 41.88% and a negative net margin of 170.26%. The firm had revenue of $13.66 million during the quarter, compared to the consensus estimate of $12.30 million. During the same quarter in the previous year, the company posted ($0.95) EPS. As a group, analysts forecast that Cellectis will post -2.37 EPS for the current fiscal year.

Large investors have recently modified their holdings of the business. Prosight Management LP boosted its holdings in Cellectis by 1.2% during the 3rd quarter. Prosight Management LP now owns 87,103 shares of the biotechnology company’s stock worth $1,098,000 after acquiring an additional 1,067 shares during the last quarter. US Bancorp DE boosted its holdings in Cellectis by 94.0% during the third quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,130 shares during the last quarter. UBS Group AG grew its position in Cellectis by 10.8% in the 3rd quarter. UBS Group AG now owns 16,302 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 1,590 shares in the last quarter. Moors & Cabot Inc. purchased a new stake in Cellectis in the 3rd quarter valued at about $287,000. Finally, Advisor Group Holdings Inc. increased its stake in Cellectis by 73.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,950 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 2,103 shares during the last quarter. Institutional investors and hedge funds own 39.04% of the company’s stock.

About Cellectis (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Further Reading

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with's FREE daily email newsletter.